IPH & BUKO Pharma Kampagne collaborates on study of German pharmaceuticals
2010 – the year was filled with new lessons in an area that impacts public health enormously, the pharma industry. At the request of Dr. Christiane Fischer of BUKO-Pharma, my colleague Amruta and myself set out collecting information on the products of three German pharmaceutical companies –Bayer, Baxter and Boehringer.
It was an interesting journey, revealing a number of lessons as we uncovered information in a systematic fashion. The most striking fact initially was how difficult it is to get information on drugs in our country. While the MIMS and CIMS are tabletop advisors to the busy practicing clinician, there is no single compendium of all drugs (generic and non-generic) sold in the country.
It was also clear that medicines are already expensive for the common man, since very few insurances pay for outpatient treatment. It is imperative that practical legal action needs to be implemented in the area of drug control, manufacturing and pricing at national and state levels.
View the publication here
